|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
MAY 29, 2006
Cerus: A Biotech Suffers Growing Pains  Breaking up can be painful, as Cerus (CERS
) (CERS) found out when it revised its ties with Baxter International (BAX
) in February. Since then, Cerus shares have swooned from 15 to 6.37. Cerus got back worldwide marketing rights to its Intercept Blood System, which treats platelets, plasma, and red blood cells from donated blood, making them safer using technology that inactivates pathogens. It will pay royalties to Baxter. Cerus won approval to sell Intercept platelets in Europe, but they are still in U.S. clinical trials. Taymour Tamaddon of T. Rowe Price (TROW
), which owns 4.4% of Cerus, says its stock is way undervalued because Intercept's huge potential in various applications is not reflected in the price. "We aren't in the stock for just a 30% gain," says Tamaddon. Christopher Raymond of Robert W. Baird, which did banking for Cerus, says Intercept platelets, already sold in small European countries, are likely to reach France and Germany in the next 24 months. He doesn't expect Cerus to make money until 2009, when he sees it earning 3 cents a share on sales of $96 million, vs. $27 million in 2006. His 12-month target: 16.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version